



#14 / SUPPL. U.S. SHEET 1 OF 1

 <p>FORM PTO-1449</p> <p><b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	<b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>		<b>ATTY. DOCKET NO.</b> ELITRA.001DV1	<b>APPLICATION NO.</b> 09/912,028
	<b>APPLICANT</b> Zyskind, et al.			
	<b>FILING DATE</b> July 23, 2001		<b>GROUP</b> 1635	




**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)


**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

EXAMINER INITIAL		
	1	Gucev, et al. 1996. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. <i>Cancer Research</i> , 56(7):1545-1550.
	2	Partial European Search Report from co-pending Application EP 01 12 4215 dated 01/28/03.
	3	Sofia, et al. "Analysis of the <i>Escherichia coli</i> genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Database accession no. XP-002228916.

S:\DOCS\DOH\DOH-7321.DOC:dmb  
030503

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 7.25.03
<b>*EXAMINER:</b> INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	